Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    11
    ...
ATC Name B/G Ingredients Dosage Form Price
N06AB03 FLUOXETINE BIOGARAN G Fluoxetine (HCl) - 20mg 20mg Capsule 239,204 L.L
L01EX01 SUTENT B Sunitinib maleate - 50mg 50mg Capsule L.L
J01CA04 AMOXICILLIN G Amoxicillin (trihydrate) - 500mg 500mg Capsule 6,199,145 L.L
N03AX16 NEUREXAL G Pregabalin - 150mg 150mg Capsule 754,856 L.L
N06AB03 NEANXETIN G Fluoxetine (HCl) - 20mg 20mg Capsule 422,351 L.L
J01CA04 AMOXICILLINE ARROW LAB G Amoxicillin (trihydrate) - 500mg 500mg Capsule 564,414 L.L
N03AX16 PLENICA G Pregabalin - 150mg 150mg Capsule 997,131 L.L
J01CA04 AMOXIDREX G Amoxicillin (trihydrate) - 500mg 500mg Capsule 254,690 L.L
N03AX16 PMS-PREGABALIN G Pregabalin - 150mg 150mg Capsule 2,534,487 L.L
N06AB03 PMS-FLUOXETINE G Fluoxetine (HCl) - 20mg 20mg Capsule 592,635 L.L
J01CA04 AMOXIDREX G Amoxicillin (trihydrate) - 500mg 500mg Capsule 7,332,097 L.L
N03AX16 PREGAFORTE 150 G Pregabalin - 150mg 150mg Capsule 1,023,880 L.L
N06AB03 PROXETIN G Fluoxetine (HCl) - 20mg 20mg Capsule 374,996 L.L
J01CA04 AMOXYCILLIN G Amoxicillin (trihydrate) - 500mg 500mg Capsule 4,073,187 L.L
N06AB03 FLUTIN G Fluoxetine (HCl) - 20mg 20mg Capsule 362,837 L.L
J01CA04 MOXILEN G Amoxicillin (trihydrate) - 500mg 500mg Capsule 3,717,068 L.L
N03AX16 LYRICA B Pregabalin - 75mg 75mg Capsule 598,010 L.L
N03AX16 LYRICA B Pregabalin - 75mg 75mg Capsule 2,131,334 L.L
N03AX16 GABRIKA 75 G Pregabalin - 75mg 75mg Capsule 793,507 L.L
L01EA03 TASIGNA B Nilotinib - 200mg 200mg Capsule 395,037,357 L.L
N03AX16 GALICA 75 G Pregabalin - 75mg 75mg Capsule 338,648 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule 310,220,984 L.L
N03AX16 NERVAX G Pregabalin - 75mg 75mg Capsule 513,348 L.L
M01AE01 ADVIL LIQUI-GELS B Ibuprofen - 200mg 200mg Capsule 464,970 L.L
N03AX16 NEUREXAL G Pregabalin - 75mg 75mg Capsule 335,577 L.L
N03AX16 NEUREXAL G Pregabalin - 75mg 75mg Capsule 637,365 L.L
N03AX16 PLENICA G Pregabalin - 75mg 75mg Capsule 697,454 L.L
J01FA10 ZITHROMAX B Azithromycin (dihydrate) - 250mg 250mg Capsule 591,291 L.L
N03AX16 PMS-PREGABALIN G Pregabalin - 75mg 75mg Capsule 1,776,560 L.L
N03AX16 PREGAFORTE 75 G Pregabalin - 75mg 75mg Capsule 793,507 L.L
    ...
    11
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025